



## ATTACHMENT A

### Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Previously presented) An isolated monoclonal antibody that binds to the propeptide of the Int1p protein of *Candida albicans* wherein the propeptide consists of the amino acid residues 1-263 of the amino acid sequence of SEQ ID NO:1, wherein the monoclonal antibody has the ability to prevent cleavage of the propeptide from the Int1p protein, and the ability to inhibit T lymphocyte activation caused by *Candida albicans*.

2-3. (Canceled)

4. (Previously presented) Isolated antisera containing the monoclonal antibody according to claim 1.

5-8. (Canceled).

9. (Previously presented) A pharmaceutical composition comprising the isolated monoclonal antibody according to claim 1 and a physiologically acceptable carrier, vehicle or diluent.

10. (Canceled)

11. (Previously presented) A diagnostic kit comprising the isolated monoclonal antibody according to claim 1 and means for detecting binding by that antibody.

12-30. (Canceled)

31. (Currently amended) The isolated monoclonal antibody according to claim 1 wherein said monoclonal antibody is capable of inhibiting T lymphocyte activationactivity in a host cell.

32. (Canceled).